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Obesity is the single greatest risk factor for nonalcoholic fatty liver disease (NAFLD).
Without intervention, most pediatric patients with NAFLD continue to gain excessive
weight, making early, effective weight loss intervention key for disease treatment and
prevention of NAFLD progression. Unfortunately, outside of a closely monitored research
setting, which is not representative of the real world, lifestyle modiﬁcation success for
weight loss in children is low. Bariatric surgery, though effective, is invasive and can
worsen NAFLD postoperatively. Thus, there is an evolving and underutilized role for
pharmacotherapy in children, both for weight reduction and NAFLD management. In this
perspective article, we provide an overview of the efﬁcacy of weight reduction on pediatric
NAFLD treatment, discuss the pros and cons of currently approved pharmacotherapy
options, as well as drugs commonly used off-label for weight reduction in children and
adolescents. We also highlight gaps in, and opportunities for, streamlining obesity trials to
include NAFLD assessment as a valuable, secondary, therapeutic outcome measure,
which may aid drug repurposing. Finally, we describe the already available, and emerging,
minimally-invasive biomarkers of NAFLD that could offer a safe and convenient alternative
to liver biopsy in pediatric obesity and NAFLD trials.
Keywords: NAFLD, pediatric, weight losing effect, pharmacotherapy, pediatric trials, pediatric NAFLD, weight
loss efﬁcacy

INTRODUCTION
With 340 million children worldwide affected by obesity (1), the rate of nonalcoholic fatty liver
disease (NAFLD) is expected to rise because obesity remains the single most signiﬁcant risk
factor for NAFLD (2). The pathophysiology of NAFLD in obesity is complex and likely involves
the interplay and dysregulation of multiple mechanisms beyond the scope of this publication
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activity daily for at least 20 minutes (with a goal of 60
minutes) (7).
In clinical practice, these lifestyle modiﬁcations show
heterogeneity in patient adherence and treatment response
(20). In pediatrics, obesity is deﬁned by body mass index
(BMI) at or above the 95th percentile for age and sex, and
treatment response assessed using the change in the percent of
the 95th percentile (%BMIp95) (21, 22). In a large national
prospective registry of children participating in non-surgical,
multicomponent, intensive behavioral clinical treatment for
obesity (n=6,454), the mean change in %BMIp95 after lifestyle
modiﬁcation was -1.88% at 4 to 6 months, -2.5% at 7 to 9
months, and -2.86% at >12 months – showing a modest decline
in weight loss over time. Only those patients who achieved -5.2%
change in %BMIp95 showed improvement in alanine
aminotransferase (ALT), a clinical biomarker of liver injury
(23). Whereas, those patients who experienced a change from
normal to abnormal ALT had an increase in %BMIp95 of 0.48%
(23), highlighting heterogeneity in treatment success.
Upon closer examination of the experience of a single
program in this registry, only one third of the 769 participants
achieved a >5% decrease in %BMIp95–the amount of BMI
change associated with improvement in ALT and liver health
(20). Increased number of clinical follow-up visits and days of
physical activity were associated with greater odds of successful
weight loss, deﬁned as achieving >5% decrease in %BMIp95 (23).
To illustrate the close clinical contact necessary for weight loss
program success, guidance for moderately intense lifestyle
modiﬁcation therapy from the United States Preventative
Services Task Force (USPSTF) recommends 26-75 patient
contact hours over a 6-12 month period (24). However, in our
experience, children with NAFLD are typically seen in clinic for
approximately one hour every 2-3 months, falling short of the
USPSTF-recommended contact hour target for weight management.

(e.g., insulin resistance, cytokine signaling, gut microbiota) (3);
however, continued abnormal weight gain is a common culprit
in fueling the disease. NAFLD affects up to 70% of children and
up to 90% of adults with obesity (2), and has become a leading
indication for liver transplant in the United States (4). Without
intervention, more than 75% of children with obesity will
continue to gain excessive weight and become adults with
obesity (5). Therefore, in addition to effective childhood weight
management strategies, readily available non-invasive diagnostic
and monitoring modalities are needed for NAFLD management,
in order to prevent obesity-associated NAFLD progression
from simple hepatic steatosis to steatohepatitis, ﬁbrosis,
cirrhosis, hepatocellular carcinoma, and end-stage liver failure
in adulthood.
Weight reduction through lifestyle modiﬁcation remains the
ﬁrst-line treatment approach for NAFLD (6). The present work
aims to review the efﬁcacy of weight reduction on pediatric
NAFLD and to illustrate opportunities for improving NAFLD
diagnosis, monitoring, and treatment outcomes through
pharmacologic interventions.

LIFESTYLE MODIFICATIONS FOR
WEIGHT REDUCTION
Lifestyle modiﬁcation for weight reduction and lasting
improvement in health outcomes requires change in multiple
areas, including diet and exercise (7). Weight loss of as little as one
kilogram has been shown to improve clinical serum biomarkers of
NAFLD in children (8), and biopsy-proven NAFLD if weight is
subsequently maintained for 24 months (9). Consequently, many
dietary interventions have been explored in pediatrics, including
portion controlled, reduced glycemic load, low carbohydrate,
meal replacement, and time restricted eating, as well as very
low calorie diets and protein sparing modiﬁed fasting for more
severe obesity (10–14). Similar to ﬁndings in adults (15), the most
effective diet for pediatric weight management is the one that can
be sustained successfully over time, with generally less adherence
observed for low carbohydrate diets and better adherence to
portion control and reduced glycemic load (10). These dietary
changes are the recommended ﬁrst step for NAFLD management,
in combination with regular moderate to high intensity exercise
(2, 6). Although there is currently insufﬁcient evidence to
recommend one type of exercise program over another for
NAFLD (16), there is some evidence to suggest that a diet low
in free sugar (17) and the Mediterranean diet speciﬁcally may
have added beneﬁt in treating NAFLD, independent of weight
loss (18). Although adherence to these two diets was exceptionally
high in some pediatric studies (8–10), this is atypical of most
other research studies (19), and likely attributable to intense
follow-up (8–10) and in-home interventions (10) that are not
available, nor practical in the clinical setting. Dietary
recommendations for weight loss and NAFLD are summarized
in Figure 1, and are generally recommended in conjunction with
exercise (>150 minutes/week moderate intensity, or >75 minutes/
week high intensity) (16), or moderate to vigorous physical
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SURGERY FOR WEIGHT REDUCTION
Bariatric surgery (e.g., laparoscopic sleeve gastrectomy) is an
effective intervention for weight reduction (25), with postsurgical weight loss of approximately 20% total body weight in
both adults (26) and children (27). Although less common in
pediatrics, bariatric surgery is becoming an increasingly
recognized option for children greater than 10 to 12 years of
age with BMI >120% of the 95th percentile (or BMI of 35 kg/m2)
and comorbid NAFLD (26, 28). Recent investigations in
adolescents suggest that bariatric surgery results in a four-fold
reduction in hepatic fat fraction, with resolution of hepatic
steatosis at 6 months post-surgery on imaging (29, 30), and
100% resolution of steatosis and 90% resolution of ﬁbrosis on
liver biopsy at 12 months post-surgery (27).
Despite its promise in treating pediatric obesity and NAFLD,
bariatric surgery also appears to worsen NAFLD in a subset of
patients. Although no pediatric data are available, in a large
meta-analysis of 32 adult studies on bariatric surgery, 19 reported
worsening or new NAFLD features, including steatosis,
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FIGURE 1 | Multiple diets have shown efﬁcacy for weight reduction in children. Ultimately, the best diet for weight management is the one that can be sustained
over time. However, both the Mediterranean (i.e., low in red meat and high in fruits, vegetables, grains, nuts, grilled chicken and ﬁsh) and the low free sugar diet have
shown added beneﬁt in pediatric NAFLD, independent of weight reduction. Generally these diets are recommended in conjunction with regular exercise (e.g., at least
150 minutes/week of moderate intensity or >75 minutes/week of high intensity exercise), or moderate to vigorous physical activity daily for at least 20 minutes (with a
target goal of 60 minutes daily).

inﬂammation, and ﬁbrosis in approximately 12% of patients
postoperatively (25). Alarmingly, no apparent risk factors could
be identiﬁed for this serious postoperative complication (25).
Thus, the risks of bariatric surgery should be balanced against the
potential for advantageous surgical outcomes for both obesity
and NAFLD, and pharmacologic agents discussed as treatment
adjuncts and/or alternative options.

prescribing stimulants for other indications common in
pediatrics (32). Phentermine also does not appear to be as
effective in achieving weight loss in adolescents as in adults
(31). As such, ligratulide–a GLP1 agonist newly approved by the
FDA in December 2020 for the treatment of pediatric obesity–
may soon emerge as the frontrunner. After somewhat
disappointing BMI reduction results in an earlier trial in
children with type II diabetes (38), results from a more recent,
randomized, controlled trial demonstrate a decrease in BMI by
1.58 kg/m 2 compared to placebo, when liraglutide was
administered to children with obesity along with lifestyle
modiﬁcations (39). Although therapeutic end-points for
NAFLD were not included in this trial, greater than 5%
reduction in BMI, previously associated with improvement in
NAFLD (20), was achieved in almost half (43%) of liraglutidetreated participants, versus 19% of participants receiving lifestyle
modiﬁcation therapy alone (39). Additional GLP1 agonists are
under investigation and it is our opinion that NAFLD assessment
ought to be considered as a secondary treatment outcome in
these trials, particularly as minimally-invasive biomarkers of
NAFLD become more readily available and mitigate the need
for liver biopsy.
The overall efﬁcacy of GLP1 agonists appears comparable to
other medications already labeled for pediatric indications and
being used off-label for weight loss in children. For example,

PHARMACOTHERAPY FOR WEIGHT
REDUCTION
Currently, two pharmaceutical agents have approval from the
United States Food and Drug Administration (FDA) for weight
loss indications in children >12 years (orlistat and liraglutide),
and one additional agent for adolescents >16 years
(phentermine) (31, 32). Of these agents, orlistat’s use is
somewhat limited by its gastrointestinal side-effect proﬁle (e.g.,
diarrhea, bloating) (33); although, it was found to be moderately
effective in decreasing BMI from 0.55 up to 4.2 kg/m2 (34–37).
Phentermine is a stimulant and a Class IV controlled substance,
necessitating increased consideration when prescribing in
children. Additional screening and monitoring is necessary in
children with congenital heart disease, cardiovascular disease,
and thyroid abnormalities similar to protocols used when
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metformin, a ﬁrst-line treatment for pediatric type II diabetes
mellitus, has been associated with a modest BMI reduction in
children (40). Recent studies looking at metformin demonstrated
a decrease of -1.07 and -1.3 kg/m2 over 6 months (41), with a
wide range of success (i.e., +0.38 to -2.52 kg/m2 BMI change)
noted in some studies (40). Although the observed variability in
treatment response may, in part, be related to variability in
adherence to concomitant lifestyle modiﬁcations, we believe it is
also related to variability in systemic drug exposure (i.e.,
pharmacokinetics) achieved from a given metformin dose
administered to an individual child (42). Additional research is
ongoing into potential sources of inter-individual variability
(e.g., genetics) in metformin pharmacokinetics and
pharmacodynamics (i.e., drug efﬁcacy). Meanwhile, the GLP1
agonist exenatide appears to show efﬁcacy comparable to
metformin, with placebo-subtracted reduction of 1.3 kg/m2
(approximately -2.7% BMI) over 3 months, and -4% BMI over
6 months, in pediatrics (41). A small clinical study of topiramate,
an anti-epilepsy drug already approved for pediatric use, also
shows a 6-month decrease in BMI similar to exenatide (-4.6%),
in 48 pediatric patients with severe obesity (43). Thus,
medications currently indicated for pediatric weight reduction,
as well as those approved for pediatric indications and
administered off-label for the purpose of weight reduction,
may have a role in weight management for pediatric patients.
However, currently available data suggest that the range of
weight loss achieved with pharmacotherapy may be only
marginally greater than lifestyle modiﬁcations alone.
In randomized controlled trials, the mean weight change for
lifestyle modiﬁcation therapy was -1.8% BMI, compared to -2.8%
BMI when therapy was combined with liraglutide or topiramate
(44). Similarly, the mean pooled reduction in BMI in response to
metformin therapy in children with obesity was -0.86 kg/m2, and
fell within the BMI reduction ranges from lifestyle modiﬁcations
alone (-0.02 to -1.10 kg/m2) (45). Importantly, on average, none
of these weight management approaches achieved a reliable >5%
reduction in BMI, deemed necessary for NAFLD improvement
(20). Thus, though weight-reduction is an important ﬁrst-line
treatment for children with NAFLD, and may be achieved
through lifestyle modiﬁcations, bariatric surgery or
pharmacotherapy, each approach is associated with substantial
variability in treatment response. This leaves a gap in universally
effective treatments for pediatric NAFLD, and a potential role for
precision therapeutics and pharmacotherapy.

obesity or obesity comorbidities–for the treatment of pediatric
NAFLD (47).
One example is the lipid-lowering drug class statins. In
addition to improving cardiovascular disease outcomes, statins
have demonstrated signiﬁcant improvement in hepatic function
for patients with obesity and NAFLD (48, 49), likely through
secondary anti-inﬂammatory effects. In adults with NAFLD,
statin therapy is well-tolerated and has a similar, low frequency
of hepatotoxicity comparable to placebo (48, 50), making it a
potential candidate for NAFLD management. However, efﬁcacy
data remain equivocal (50) and genotype-stratiﬁed investigations
may be necessary to identify therapeutic target ranges
appropriate for NAFLD treatment indications.
It would be remiss not to mention oxidative stress as a
potential therapeutic target in NAFLD management. Antioxidants (e.g. vitamin E, omega-3 fatty acids) have been used
both for the treatment of pediatric weight reduction and NAFLD,
with mixed results (8, 51–53). In one longitudinal, randomized,
placebo-controlled trial, vitamin E did not demonstrate
advantage over weight reduction through lifestyle modiﬁcations
for NAFLD or obesity (8). In another longitudinal, placebocontrolled trial of vitamin E vs. metformin, neither agent resulted
in sustained ALT reduction (51). However, resolution of
steatohepatitis was signiﬁcantly higher with vitamin E
compared to placebo, even though BMI reduction was
equivocal (51). Conversely, in a trial of omega-3 fatty acids,
children treated with omega-3s were more likely to have BMI
reduction compared to placebo, but reduction in ALT was
equivocal (52, 53). Collectively, these studies indicate equipoise
in anti-oxidant efﬁcacy for NAFLD and highlight the need for
further study.
Many other agents, already being used on and off-label for
weight reduction, have been proposed to have therapeutic beneﬁt
for NAFLD (54), though few have been evaluated in children.
These include orlistat; GLP1 agonists, such as liraglutide,
semaglutide, and exenatide; and SGLT2 inhibitors. While some
pediatric studies of orlistat have shown select improvement in
serum liver injury markers (55), the majority of studies have not
examined the effect of orlistat on liver adiposity or
histopathology. Available data to date demonstrate no clear
improvement in liver pathology that is independent of orlistatinduced weight loss (54), making orlistat a questionable drug
candidate for primary NAFLD indications in children (56). To
our knowledge, liraglutide and other GLP1 agonists have not
been evaluated as pharmacotherapy for pediatric NAFLD;
however, multiple studies in adults demonstrate promising
improvement in hepatic steatosis and liver injury markers
associated with GLP1 agonist treatment (54, 57). It is unclear
whether this effect on NAFLD is independent of weight-loss, a
caveat that extends to SGLT2 inhibitors, which also demonstrate
some beneﬁt for NAFLD treatment in adults (58). Parallel studies
in pediatrics are indicated, particularly now that liraglutide is
approved for weight loss indications in children, and more
agents may be on the horizon soon.
Metformin, a drug already FDA-approved for type II diabetes
in children and used off-label for pediatric weight loss (40, 41),

PHARMACOTHERAPY FOR NAFLD
Currently, there are no FDA-approved medications for pediatric
NAFLD. However, the landscape of potential therapeutic agents
for NAFLD is evolving rapidly and showing promise, as
highlighted in recently published reviews (26, 46) beyond the
scope of this publication. In addition to novel therapeutic agents
(e.g., obeticholic acid, ﬁbroblast growth factor 19 & 21 analogs,
thyroid hormone receptor-b agonists), there is also interest in
repurposing existing drugs–already approved for pediatric
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has also shown some promise for repurposing in pediatric
NAFLD. In a study of lifestyle modiﬁcations combined with
either metformin or placebo in children with obesity and insulin
resistance +/- NAFLD, the metformin group demonstrated a
signiﬁcant decrease in NAFLD scores and NAFLD prevalence,
while the placebo group experienced an increase in both (59).
Other studies in pediatrics using metformin at lower doses
demonstrated isolated improvement in hepatic ballooning (51)
or lobular inﬂammation (9) on histopathology, but failed to show
an overall improvement in steatosis or NAFLD scores, suggesting
that the effects of metformin on NAFLD may be dose-dependent.
Improvement in serum ALT has been equivocal between studies,
with 2 out of 4 pediatric studies demonstrating improvement in
ALT (59, 60). However, this is likely because ALT, along with
other currently available clinical markers of liver injury, lacks
speciﬁcity for NAFLD (25).

recurrent monitoring of NAFLD. Instead, serum ALT is the most
commonly used biomarker of NAFLD, but it is non-speciﬁc and
can be normal in >80% of patients with NAFLD (25). Therefore,
minimally-invasive and highly-speciﬁc biomarkers are urgently
needed to diagnose and monitor NAFLD.
In the past decade, several new, potential biomarkers of NAFLD
have been identiﬁed by serum proteomics/metabolomics analyses
(61, 62). Based on their origin, these markers can be grouped into
hepatokines, adipokines, and other cytokines. Although detailed
review of these novel biomarker candidates is beyond the scope of
this publication, the most promising biomarkers are summarized
in Table 1. In addition, serum bile acids (BAs) are highlighted as
another emerging class of biomarkers.
BAs are synthesized in the liver, excreted into the bile,
metabolized by the intestinal microbiome, and undergo several
enterohepatic recirculations. Therefore, changes in the BA
metabolome could be pathognomonic for various stages of
NAFLD. The ratio of the primary BAs, cholic acid and
chenodeoxycholic acid, is higher in patients with simple
steatosis, as well as more advanced NAFLD (90). Compared to
healthy controls, total fasting and postprandial primary BAs, and
the ratios of taurine- and glycine-conjugated BAs, are
consistently higher in the sera of adults with nonalcoholic

MINIMALLY-INVASIVE BIOMARKERS
OF NAFLD
The diagnostic gold standard for NAFLD in children is liver
biopsy. However, liver biopsy is invasive and not practical for

TABLE 1 | Potential Biomarkers for Nonalcoholic Fatty Liver Disease.
Biomarkers & biomarker candidates

Type/origin

Changes in NAFLD
steatosis

Correlations and changes in other
NAFLD-related conditions

Adiponectin

Adipokine

↓

↓ in inﬂammation
↓ in ﬁbrosis

Chemerin
Leptin

Adipokine
Adipokine

↑
↑

Resistin

Adipokine

(↑)

Visfatin

Adipokine

↑

Leptin/adiponectin ratio

Adipokine

Irsin

Adipokine

↑
NAFLD > obese children
↑

–
↑ in inﬂammation
↑ in ﬁbrosis
( ↑ ) in inﬂammation
( ↑ ) in ﬁbrosis
( ↑ ) in inﬂammation
( ↑ ) in ﬁbrosis
positively correlates with triglyceride

Fetuin- A, a2-HS-glycoprotein (AHSG)

Hepatokine

↑

Fibroblast growth factor 21 (FGF-21)

Hepatokine

↑

Selenoprotein P (SeP)

Hepatokine

Sex hormone-binding globulin (SHBG)
Leukocyte derived chemotaxin 2 (LECT2)
Cathepsin D (CatD)
Adropin
Retinol-binding protein 4 (RBP4)
Tumor necrosis factor alpha (TNF-a)

Hepatokine
Hepatokine
Hepatokine
Hepatokine
Hepatokine, Adipokine
Inﬂammatory cytokine

↑ in children
↓ in adults
↓
↑
↓
↓
↓
↑

Zonulin

Intestinal peptide

Interleukin-18 (IL-18)

cytokine

↑
NAFLD > obese children
↑
NAFLD > obese children

References

(63)
(64, 65)
(66)
(67)
(68, 69)
(70)

( ↑ ) in inﬂammation
( ↑ ) in ﬁbrosis
positively correlates with HOMA-IR (insulin
resistance index)
positively correlates with hepatic fat fraction
and hepatic triglycerides
negatively correlates with adiponectin

(71, 72)

–
↑ in insulin resistance
↓ in inﬂammation
–
↓ in insulin resistance & T2DM
↑ in inﬂammation
↑ in ﬁbrosis
↑ in inﬂammation
& NASH
–

(77)
(80, 81)
(82)
(83)
(84)
(85, 86)

(73, 74)
(75–77)
(77–79)

(87, 88)
(89)

↑ indicates marker increase; ↓ indicates marker decrease. NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; T2DM, type II diabetes mellitus; HOMA-IR,
homeostatic model assessment for insulin resistance.
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steatohepatitis (NASH) (91). However, the role of secondary BAs
as potential biomarkers remains debated, as the two studies
above showed different results. Puri et al. observed lower total
secondary BAs in adults with NASH compared to controls (90),
whereas Ferslew et al. observed higher secondary BAs (91). In
pediatrics, BAs study results are sparse and inconsistent, but
could offer a valuable, minimally-invasive modality for NAFLD
monitoring during treatment trials. Signiﬁcantly lower total
serum BA concentrations were found in one pediatric study of
hepatic steatosis (92), but not in others (93, 94). Notably, two of
these studies demonstrated decreased concentrations of glycineand taurine-conjugated deoxycholic acid in children with
NAFLD steatosis and/or NASH, compared to healthy controls
(92, 93). The third study also found serum concentrations of
glycine conjugated deoxycholic acid to be lower in children with
NAFLD, but not in children with NASH (94). Together, these
observations suggest that bile acid homeostasis in pediatric
NAFLD may be distinct from the adult disease phenotype.
Therefore, BAs results should not be extrapolated from adults
to children, and further investigation in pediatric patients
is warranted.
While serum biomarkers of NAFLD remain under
investigation, several liver imaging biomarkers have become
available. Magnetic resonance proton density fat fraction (MRPDFF) is a non-invasive technique that quantiﬁes the percentage
of fat within a given volume of tissue. It correlates closely with
steatosis grade on liver biopsy in children (95) and accurately
captures longitudinal changes in pediatric NAFLD over time
(96). However, it is only available in specialized tertiary care
centers and is expensive. Ultrasound techniques for fat
quantiﬁcation are not yet widely available, but could offer a
cheaper, more accessible alternative to magnetic resonance fat
quantiﬁcation, and facilitate more consistent and better quality
disease monitoring for pediatric obesity and NAFLD trials.
For those imaging biomarkers that are widely available, one
consistent shortcoming is that they perform best for tracking
more severe stages of NAFLD/NASH, typical of adult disease.
Grayscale ultrasound has been used for many years as a
qualitative estimate of hepatic fat content. However, this
technique is unreliable and non-speciﬁc for hepatic fat
quantiﬁcation, due to overlap in appearance between fatty and
ﬁbrotic liver (97, 98). Similarly, although both ultrasound and
magnetic resonance elastography can quantify liver stiffness as a
surrogate for ﬁbrosis, NAFLD presents a challenge because
measurement values are affected by both fat and ﬁbrosis (99).
Therefore, an ideal pediatric imaging surveillance program
would incorporate quantitative imaging measurements that
could discriminate fat and ﬁbrosis.

induce and sustain such weight loss are low (19, 20). Bariatric
surgery is becoming increasingly recognized as an option for
weight reduction in children (26), but it is invasive, and there is
an unpredictable subset of patients who experience worsening
liver ﬁbrosis and NAFLD progression after surgery (25). This
leaves room for pharmacologic interventions to aid with weight
loss in pediatric obesity to treat and prevent NAFLD.
Without intervention, most pediatric patients with NAFLD
continue to gain excessive weight (5) and become adults with
NAFLD. Thus, inclusion of children and adolescents in
pharmacology trials of novel weight-loss and NAFLD
treatments is paramount. Repurposing drugs already labeled
for pediatric use in comorbidities associated with obesity may
be a complementary strategy to expand pediatric NAFLD
treatment options beyond lifestyle modiﬁcations or bariatric
surgery. Importantly, incorporation of NAFLD treatment endpoints into obesity trials up-front would streamline efforts to
assess a given drug’s efﬁcacy for pediatric NAFLD, as well as
obesity, and potentially help discriminate drug effect from
weight-loss effect on NAFLD.
Regardless of the treatment approach selected, to streamline
and facilitate treatment trials in pediatrics, minimally-invasive,
highly-speciﬁc biomarkers of NAFLD are urgently needed to
augment advanced imaging techniques that offer an alternative
to liver biopsy, but are expensive and inaccessible in most clinical
settings. A concerted effort must be made to include children in
NAFLD biomarkers and therapeutics trials in order to intervene
early and effectively in disease progression that is fueled by
continued excessive weight gain from childhood into
adulthood. Best strategies for including children in NAFLD
trials are under development, as referenced in a draft guidance
for industry from the FDA (100), and additional tips for optimal
patient selection and age-appropriate therapeutic end-points can
be found in a recent review by Alkhouri et al. (101).

DISCUSSION
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